22 hours ago · Novo Nordisk plans further clinical development of amycretin for obesity and overweight treatment. ... Amycretin (Novo Norisk) led to a reduction in body weight across the 20-week, 28-week, and 36-week periods, with weight loss of up to 22%, according to results from a randomized control trial. 1.

Jan 27, 2025 · About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes. Amycretin is developed for oral and subcutaneous administration.

Sep 12, 2024 · Amycretin, a new weight loss drug developed by Novo Nordisk, has shown promising early results and is potentially more effective than the company’s established treatments, Ozempic and Wegovy.

6 days ago · With amycretin, Novo Nordisk expects to improve on the efficacy of its blockbuster drug semaglutide, sold under the brand names Ozempic and Wegovy. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of drugs that have rapidly gained in popularity in recent years due to their significant weight loss effects. In comparison ...

Jan 24, 2025 · Topline data from a Phase 1b/2a clinical trial were positive for once-weekly subcutaneous amycretin, a glucagon-like peptide-1 (GLP-1) and amylin receptor agonist intended for the treatment of overweight or obesity. 1. Announced by Novo Nordisk on January 24, 2025, amycretin demonstrated a safety profile similar to other incretin-based therapies, with an …

Jan 24, 2025 · In December, Novo said its CagriSema drug, which is far more advanced in development than amycretin, led to 22.7% weight loss after 68 weeks, below the 25% the company had expected.

2 days ago · Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...

Jan 24, 2025 · The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

Sep 23, 2024 · In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months. Amycretin targets GLP-1 receptors and a second hormone called amylin. Amylin appears to act in the brain, rather than in the gut. It’s possible that amylin can control appetite with fewer gastrointestinal side effects.

Sep 11, 2024 · Participants taking Novo Nordisk’s experimental weight loss treatment amycretin lost up to 13% of their body weight over 12 weeks in an early stage Phase 1 clinical trial, according to an ...